The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C., Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus...
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
Seaking AlphaSeeking Alpha / Seaking Alpha 3 hours ago 1 Views
Comments